10 completed, 7 terminated, 5 not yet recruiting, 5 unknown. 36 Phase 3, 13 Phase 2.
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-01 | 2026-10-13 |
| Autologous Circulating Extracellular Vesicles for Total-Type Sudden Sensorineural Hearing Loss autologous circulating extracellular vesicles, Glucocorticoids - Sudden Sensorineural Hearing Loss (SSNHL) | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 146 | 2026-09-15 | 2026-10-16 |
| Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss Aspirin + Acid folic, Placebo Aspirin + Placebo Acid folic - Sudden Sensorineural Hearing Loss | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 142 | 2026-04-01 | 2026-01-14 |
| Evaluation of Oral Corticosteroid Therapy in Idiopathic Sudden Unilateral Hearing Loss. prednisone - oral corticosteroid 1mg/kg/D for 1 week, Placebo - Sudden Sensorineural Hearing Loss | Phase 3 | Not yet recruiting | Centre Hospitalier Universitaire de Besancon | 430 | 2025-11-01 | 2025-07-24 |
| SPI-1005 for the Treatment of Meniere's Disease (Open Label) Ebselen - Meniere's Disease, Ménière's Disease | Phase 3 | Active not recruiting | Sound Pharmaceuticals, Incorporated | 200 | 2025-10-29 | 2026-07-13 |
| A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy Spectacle Hearing Aid - Hearing Loss Mixed | Phase 2 / Phase 3 | Recruiting | Nuance Hearing | 89 | 2025-07-27 | 2025-12-15 |
| Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease Isosorbide oral solution, Placebo - Meniere´s Disease | Phase 2 / Phase 3 | Not yet recruiting | Lunan Better Pharmaceutical Co., LTD. | 234 | 2024-12-30 | 2025-01-09 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease Methylprednisolon, Placebo - Meniere Disease | Phase 3 | Recruiting | Leiden University Medical Center | 148 | 2023-10-01 | 2023-12-04 |
| Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism - Sensorineural Hearing Loss, Bilateral | Phase 3 | Recruiting | Eli Lilly and Company | 48 | 2023-09-15 | 2026-09-29 |
| Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss. Platelet Rich Plasma, local anesthesia in external auditory canal, Intratympanic Injection - Hearing Loss, Sudden, Hearing Loss, Sensorineural | Phase 2 / Phase 3 | Unknown | Assiut University | 23 | 2023-06-01 | 2023-04-19 |
| ACHIEVE Brain Health Follow-Up Study Hearing intervention, Successful aging/delayed hearing intervention - Aging, Cognitive Decline | Phase 3 | Active not recruiting | Johns Hopkins University | 629 | 2023-01-12 | 2026-07-21 |
| SPI-1005 for the Treatment of Meniere's Disease Ebselen, Placebo - Meniere Disease, Ménière | Phase 3 | Completed | Sound Pharmaceuticals, Incorporated | 220 | 2022-08-02 | 2026-07-23 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss SENS-401, Placebo Oral Tablet - Severe Sudden Sensorineural Hearing Loss | Phase 2 / Phase 3 | Completed | Sensorion | 115 | 2019-02-15 | 2023-03-01 |
| Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery Dexamethasone, Sterile isotonic saline solution - Sensorineural Hearing Loss, Cochlear Implant | Phase 3 | Unknown | Hospital Italiano de Buenos Aires | 20 | 2017-08-09 | 2017-12-29 |
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 20 | 2016-12-01 | 2016-08-29 |
| Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo - Hearing Loss, Idiopathic Sudden Sensorineural | Phase 3 | Terminated | Auris Medical, Inc. | 56 | 2016-06-01 | 2020-08-07 |
Showing 20 of 36. Sign in to see all of them.
Hearing Loss, Sensorineural (10) · Hearing Loss, Sudden (9) · Tinnitus (7) · Deafness (6) · Retinitis Pigmentosa (5) · Usher Syndromes (5) · Meniere Disease (4) · Dizziness (3) · Hearing Disorders (3) · Vertigo (3) · Cytomegalovirus Infections (2) · Ear Diseases (2) · Eye Abnormalities (2) · Eye Diseases (2)
Pathological Conditions, Signs and Symptoms (36) · Nervous System Diseases (35) · Neurologic Manifestations (35) · Ear Diseases (34) · Otorhinolaryngologic Diseases (34) · Sensation Disorders (34) · Signs and Symptoms (34) · Hearing Disorders (33) · Hearing Loss, Sensorineural (7) · Abnormalities, Multiple (5) · Blindness (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Deaf-Blind Disorders (5)
Acetylcysteine (3) · D-JNKI-1 (2) · Fumigant 93 (2) · Intravitreal Injections (2) · Valganciclovir (2) · ebselen (2) · Adrenal Cortex Hormones (1) · Anesthesia, Local (1) · Aspirin (1) · Bed Rest (1) · Deferiprone (1) · Dexamethasone (1) · Famciclovir (1) · Folic Acid (1) · Glucocorticoids (1)
Assistance Publique - Hôpitaux de Paris (2) · Dr. Ann C.T.M. Vossen (2) · Johns Hopkins University (2) · Laboratoires Thea (2) · Nacuity Pharmaceuticals, Inc. (2) · Sound Pharmaceuticals, Incorporated (2) · Assiut University (1) · Auris Medical AG (1) · Auris Medical, Inc. (1) · Centre Hospitalier Universitaire de Besancon (1) · Eli Lilly and Company (1) · Hadassah Medical Organization (1) · Hospital Italiano de Buenos Aires (1) · House Research Institute (1) · Leiden University Medical Center (1)
United States (12) · France (5) · Netherlands (5) · United Kingdom (5) · Canada (4) · Germany (4) · Israel (4) · Austria (2) · Bulgaria (2) · Switzerland (2) · Taiwan (2) · Turkey (Türkiye) (2) · Argentina (1) · China (1) · Czechia (1)
Ann CT Vossen, Dr. (1) · Anne Marie Oudesluys-Murphy, Prof. Dr. (1) · Benoit Mongourdin, PH (1) · Chen-Chi Wu, MD (1) · Chuan-Jen Hsu, MD (1) · David Zangen, Professor (1) · Dr. Jeffrey Harris (1) · Dr. Patrick Brookhouser (1) · Eldar Carmel, MD (1) · Emmanuel Cuny, MD (1) · Frank R Lin, MD, PhD (1)
PMID 19172627, PMID 21610239, PMID 22805100, PMID 25017670, PMID 25073872, PMID 29457537, PMID 39209781, PMID 41026887, PMID 41282901, PMID 42635483
1UG1EY033293 (1), 2009 (1), R01AG076518 (1), U01DC003209 (1), U01DC006296 (1)